Therapix Biosciences has entered into an agreement with the Hebrew University's technology transfer company Yissum to obtain an exclusive worldwide license for an intranasal formulation of cannabinoids developed by Elka Touitou of the university's Institute of Drug Research, the company said. The news comes one week after the company, which is developing cannabinoids … [Read more...] about Therapix Biosciences licenses intranasal cannabinoid formulation from Hebrew University
News
US subsidiary of MedPharm now open
UK-based formulation development company MedPharm has announced the opening of its new US subsidiary, MP Pharma Services, located in Durham, NC. MedPharm offers services for transdermal and topical, including inhaled and intranasal, formulations. MP Pharma Services is led by former Stiefel Director of Topical Delivery Jon Lenn. MedPharm CEO Andrew Muddle … [Read more...] about US subsidiary of MedPharm now open
Approval packages for Stiolto Respimat and Spiriva Respimat now available
The FDA has made the approval packages for Boehringer Ingelheim's Stiolto Respimat and Spiriva Respimat available on its website. The Stiolto Respimat tiotropium bromide/olodaterol SMI, which is marketed as Spiolto Respimat in Europe, was approved for the treatment of COPD by the FDA in May 2015. Spiriva Respimat tiotropium bromide SMI was approved for the treatment … [Read more...] about Approval packages for Stiolto Respimat and Spiriva Respimat now available
FDA accepts Teva NDAs for fluticasone propionate/salmeterol and FP monotherapy DPIs
Teva has announced the FDA's acceptance of the company’s NDAs for fluticasone propionate (FP)/salmeterol and FP monotherapy DPIs for the treatment of asthma. Both products are delivered using the breath-activated RespiClick inhaler. In late 2015, Teva announced positive data from Phase 3 studies of both products. The FDA is expected to take action on both … [Read more...] about FDA accepts Teva NDAs for fluticasone propionate/salmeterol and FP monotherapy DPIs
US Centers for Disease Control (CDC) advises against using FluMist for 2016-17
The Advisory Committee on Immunization Practices (ACIP) of the US Centers for Disease Control and Prevention (CDC) has recommended against the use of MedImmune's FluMist Quadrivalent Live Attenuated Influenza Vaccine (FluMist Quadrivalent) for the 2016-2017 influenza season because the intranasal vaccine has failed to demonstrate significant effectiveness in children … [Read more...] about US Centers for Disease Control (CDC) advises against using FluMist for 2016-17
Savara Pharmaceuticals acquires Serendex, inhaled molgramostim
AeroVanc developer Savara Pharmaceuticals has acquired Serendex Pharmaceuticals, which is developing Molgradex inhaled granulocyte-macrophage colony-stimulating factor (molgramostim) for the treatment of autoimmune pulmonary alveolar proteinosis (PAP). Serendex announced in September 2015 that it was initiating a Phase 2 clinical trial of Molgradex, which is delivered … [Read more...] about Savara Pharmaceuticals acquires Serendex, inhaled molgramostim
Ferrer completes merger with Alexza
In May 2016, Grupo Ferrer announced that it would acquire inhaled drug company Alexza Pharmaceuticals; as of June 21, 2016, the company says, Ferrer Pharma has merged into Alexza Pharmaceuticals, with Alexza now a wholly owned subsidiary of Ferrer. Ferrer already marketed Alexza's Staccato inhaled loxapine in much of the world and had become Alexza's largest … [Read more...] about Ferrer completes merger with Alexza
Phase 3 study shows GSK’s FF/UMEC/VI combination improves lung function and quality of life better than Symbicort
GlaxoSmithKline and Innoviva have presented data from the FULFIL study of its fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) DPI versus Symbicort for COPD, reiterating that the data support the company's plans to file an NDA for the product by the end of the year as recently announced as well as filing for approval in the EU by the end of 2016. The study met … [Read more...] about Phase 3 study shows GSK’s FF/UMEC/VI combination improves lung function and quality of life better than Symbicort
Adherium SmartInhaler technology used in new AstraZeneca study
Adherium has announced that AstraZeneca will use Adherium’s SmartTouch Symbicort device in an upcoming 12-month clinical study of adherence in patients with COPD that is expected to enroll almost 400 US COPD patients. In July 2015, Adherium announced a deal to supply SmartInhaler technology for AstraZeneca's asthma and COPD patient support programs. According to … [Read more...] about Adherium SmartInhaler technology used in new AstraZeneca study
Consort reports growth for both Bespak and Aesica
In its annual report for the fiscal year ended 30 April 2016, Consort Medical reports that its subsidiary Bespak experienced revenue growth of almost 11%, and CDMO Aesica, which Consort acquired in November 2014, experienced "significant growth" and "encouraging EBIT margin growth." Overall revenue for Consort was up 50.4% to £276.9 million. Bespak's MDI growth was … [Read more...] about Consort reports growth for both Bespak and Aesica